189 related articles for article (PubMed ID: 34862715)
1. TITE-gBOIN: Time-to-event Bayesian optimal interval design to accelerate dose-finding accounting for toxicity grades.
Takeda K; Xia Q; Liu S; Rong A
Pharm Stat; 2022 Mar; 21(2):496-506. PubMed ID: 34862715
[TBL] [Abstract][Full Text] [Related]
2. TITE-gBOIN-ET: Time-to-event generalized Bayesian optimal interval design to accelerate dose-finding accounting for ordinal graded efficacy and toxicity outcomes.
Takeda K; Yamaguchi Y; Taguri M; Morita S
Biom J; 2023 Oct; 65(7):e2200265. PubMed ID: 37309248
[TBL] [Abstract][Full Text] [Related]
3. TITE-BOIN-ET: Time-to-event Bayesian optimal interval design to accelerate dose-finding based on both efficacy and toxicity outcomes.
Takeda K; Morita S; Taguri M
Pharm Stat; 2020 May; 19(3):335-349. PubMed ID: 31829517
[TBL] [Abstract][Full Text] [Related]
4. gBOIN-ET: The generalized Bayesian optimal interval design for optimal dose-finding accounting for ordinal graded efficacy and toxicity in early clinical trials.
Takeda K; Morita S; Taguri M
Biom J; 2022 Oct; 64(7):1178-1191. PubMed ID: 35561046
[TBL] [Abstract][Full Text] [Related]
5. Time-to-Event Bayesian Optimal Interval Design to Accelerate Phase I Trials.
Yuan Y; Lin R; Li D; Nie L; Warren KE
Clin Cancer Res; 2018 Oct; 24(20):4921-4930. PubMed ID: 29769209
[TBL] [Abstract][Full Text] [Related]
6. Two-stage subgroup-specific time-to-event (2S-Sub-TITE): An adaptive two-stage time-to-toxicity design for subgroup-specific dose finding in phase I oncology trials.
McGovern A; Chapple AG; Ma C
Pharm Stat; 2022 Nov; 21(6):1138-1148. PubMed ID: 35560864
[TBL] [Abstract][Full Text] [Related]
7. An adaptive gBOIN design with shrinkage boundaries for phase I dose-finding trials.
Mu R; Hu Z; Xu G; Pan H
BMC Med Res Methodol; 2021 Dec; 21(1):278. PubMed ID: 34895153
[TBL] [Abstract][Full Text] [Related]
8. Escalation with overdose control using all toxicities and time to event toxicity data in cancer Phase I clinical trials.
Chen Z; Cui Y; Owonikoko TK; Wang Z; Li Z; Luo R; Kutner M; Khuri FR; Kowalski J
Contemp Clin Trials; 2014 Mar; 37(2):322-32. PubMed ID: 24530487
[TBL] [Abstract][Full Text] [Related]
9. TITE-BOIN12: A Bayesian phase I/II trial design to find the optimal biological dose with late-onset toxicity and efficacy.
Zhou Y; Lin R; Lee JJ; Li D; Wang L; Li R; Yuan Y
Stat Med; 2022 May; 41(11):1918-1931. PubMed ID: 35098585
[TBL] [Abstract][Full Text] [Related]
10. A generalized Bayesian optimal interval design for dose optimization in immunotherapy.
Xia Q; Takeda K; Yamaguchi Y; Zhang J
Pharm Stat; 2024 Jan; ():. PubMed ID: 38295856
[TBL] [Abstract][Full Text] [Related]
11. DICE: A Bayesian model for early dose finding in phase I trials with multiple treatment courses.
Ursino M; Biard L; Chevret S
Biom J; 2022 Dec; 64(8):1486-1497. PubMed ID: 34729815
[TBL] [Abstract][Full Text] [Related]
12. Time-to-event calibration-free odds design: A robust efficient design for phase I trials with late-onset outcomes.
Jin H; Yin G
Pharm Stat; 2023; 22(5):773-783. PubMed ID: 37095681
[TBL] [Abstract][Full Text] [Related]
13. BOIN-ET: Bayesian optimal interval design for dose finding based on both efficacy and toxicity outcomes.
Takeda K; Taguri M; Morita S
Pharm Stat; 2018 Jul; 17(4):383-395. PubMed ID: 29700965
[TBL] [Abstract][Full Text] [Related]
14. BOIN-ETC: A Bayesian optimal interval design considering efficacy and toxicity to identify the optimal dose combinations.
Kakizume T; Takeda K; Taguri M; Morita S
Stat Methods Med Res; 2024 Apr; 33(4):716-727. PubMed ID: 38444354
[TBL] [Abstract][Full Text] [Related]
15. A novel framework of Bayesian optimal interval design for phase I trials with late-onset toxicities.
Zhou H; Chen C; Sun L; Zeng Z
Contemp Clin Trials; 2021 Jun; 105():106404. PubMed ID: 33862287
[TBL] [Abstract][Full Text] [Related]
16. Surv-CRM-12: A Bayesian phase I/II survival CRM for right-censored toxicity endpoints with competing disease progression.
Andrillon A; Chevret S; Lee SM; Biard L
Stat Med; 2022 Dec; 41(29):5753-5766. PubMed ID: 36259523
[TBL] [Abstract][Full Text] [Related]
17. Adaptive design for identifying maximum tolerated dose early to accelerate dose-finding trial.
Kojima M
BMC Med Res Methodol; 2022 Apr; 22(1):97. PubMed ID: 35382745
[TBL] [Abstract][Full Text] [Related]
18. An adaptive multi-stage phase I dose-finding design incorporating continuous efficacy and toxicity data from multiple treatment cycles.
Du Y; Yin J; Sargent DJ; Mandrekar SJ
J Biopharm Stat; 2019; 29(2):271-286. PubMed ID: 30403559
[TBL] [Abstract][Full Text] [Related]
19. A Bayesian dose-finding design incorporating toxicity data from multiple treatment cycles.
Yin J; Qin R; Ezzalfani M; Sargent DJ; Mandrekar SJ
Stat Med; 2017 Jan; 36(1):67-80. PubMed ID: 27633877
[TBL] [Abstract][Full Text] [Related]
20. GUIP1: a R package for dose escalation strategies in phase I cancer clinical trials.
Dinart D; Fraisse J; Tosi D; Mauguen A; Touraine C; Gourgou S; Le Deley MC; Bellera C; Mollevi C
BMC Med Inform Decis Mak; 2020 Jun; 20(1):134. PubMed ID: 32580715
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]